中国人非小细胞肺癌EGFR基因突变的研究  

Mutational Analysis of EGFR in Chinese Patients with NSCLCs

作　　者：姜斌[1] 朱冠山 刘峰[1] 龚圣济[1] 姚宝娣[1] 钟镭[3] 朱忠政[4] 曾骥孟 

机构地区：[1]上海第二医科大学宝钢医院肿瘤科,上海201900 [2]上海基康生物技术有限公司 [3]第二军医大学长征医院胸心外科 [4]解放军第113医院病理科

出　　处：《上海第二医科大学学报》2005年第11期1148-1150,共3页Acta Universitatis Medicinalis Secondae Shanghai

摘　　要：目的研究中国人非小细胞肺癌表皮生长因子受体(EGFR)基因突变的情况。方法采用PCR扩增和基因测序,检测101例非小细胞肺癌(NSCLCs)EGFR外显子18、19和21的突变情况,并与国外报道的数据进行比较,同时分析其突变与临床特征的关系。结果共检测26例EGFR突变(25.7%),显著高于西方国家报道的数字,其中以腺癌、非吸烟者和女性突变率较高。结论中国人NSCLCs的EGFR突变率高于西方人种,更适宜靶向药物的治疗。Objective To investigate gene mutations of the epidermal growth factor receptor （EGFR） in Chinese non-small cell lung cancers （NSCLCs）. Methods Mutations of exons 18, 19 and 21 of the EGFR in 101 NSCLCs were detected by PCR-amplifying and gene sequencing, and the relationship between mutations and clinical characters of NSCLCs were analyzed. Results Overall, we detected 26 EGFR mutations （25.7%） , and found mutation frequencies in adenocarcinomas, nonsmoker and female were high. Conclusion Our data suggest that mutation frequency of EGFR in lung adenocarcinomas from Chinese patients was higher than that in western ethnicities.

关 键 词：表皮生长因子受体 非小细胞肺癌 基因突变 

分 类 号：R734.2[医药卫生—肿瘤] Q754[医药卫生—临床医学]